AnaptysBio (ANAB) Stock Price Up 7.5%

Shares of AnaptysBio Inc (NASDAQ:ANAB) rose 7.5% on Thursday . The stock traded as high as $114.47 and last traded at $111.29. Approximately 824,400 shares changed hands during trading, an increase of 116% from the average daily volume of 381,614 shares. The stock had previously closed at $103.52.

ANAB has been the topic of several recent analyst reports. Zacks Investment Research raised AnaptysBio from a “sell” rating to a “hold” rating and set a $74.00 target price on the stock in a research note on Friday, November 10th. SunTrust Banks began coverage on AnaptysBio in a research note on Wednesday, November 15th. They issued a “buy” rating and a $115.00 price objective on the stock. Royal Bank of Canada boosted their price objective on AnaptysBio from $40.00 to $79.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 10th. Credit Suisse Group boosted their price objective on AnaptysBio from $38.00 to $85.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 10th. Finally, Robert W. Baird set a $69.00 price objective on AnaptysBio and gave the stock a “buy” rating in a research note on Wednesday, October 11th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $88.00.

The company has a current ratio of 10.77, a quick ratio of 10.77 and a debt-to-equity ratio of 0.09.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.45) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.47) by $0.02. equities analysts predict that AnaptysBio Inc will post -1.72 EPS for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the company. Perceptive Advisors LLC raised its position in shares of AnaptysBio by 3.2% during the third quarter. Perceptive Advisors LLC now owns 982,269 shares of the biotechnology company’s stock worth $34,330,000 after purchasing an additional 30,000 shares during the period. VHCP Management II LLC acquired a new stake in shares of AnaptysBio during the third quarter worth $5,856,000. Evercore Wealth Management LLC acquired a new stake in shares of AnaptysBio during the third quarter worth $100,000. California State Teachers Retirement System raised its position in shares of AnaptysBio by 104.2% during the third quarter. California State Teachers Retirement System now owns 19,400 shares of the biotechnology company’s stock worth $678,000 after purchasing an additional 9,900 shares during the period. Finally, Schwab Charles Investment Management Inc. raised its position in shares of AnaptysBio by 69.3% during the third quarter. Schwab Charles Investment Management Inc. now owns 32,846 shares of the biotechnology company’s stock worth $1,148,000 after purchasing an additional 13,444 shares during the period. 75.48% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Stock Observer and is the sole property of of Stock Observer. If you are accessing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece can be viewed at https://www.thestockobserver.com/2018/01/13/anaptysbio-anab-stock-price-up-7-5.html.

About AnaptysBio

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply